These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24500525)

  • 1. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model.
    Wang Z; Halbert CL; Lee D; Butts T; Tapscott SJ; Storb R; Miller AD
    Gene Ther; 2014 Apr; 21(4):363-70. PubMed ID: 24500525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local gene delivery and methods to control immune responses in muscles of normal and dystrophic dogs.
    Wang Z; Tapscott SJ; Storb R
    Methods Mol Biol; 2011; 709():265-75. PubMed ID: 21194034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production.
    Halbert CL; Metzger MJ; Lam SL; Miller AD
    Gene Ther; 2011 Apr; 18(4):411-7. PubMed ID: 21160534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.
    Wang Z; Allen JM; Riddell SR; Gregorevic P; Storb R; Tapscott SJ; Chamberlain JS; Kuhr CS
    Hum Gene Ther; 2007 Jan; 18(1):18-26. PubMed ID: 17176210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.
    Bowles DE; McPhee SW; Li C; Gray SJ; Samulski JJ; Camp AS; Li J; Wang B; Monahan PE; Rabinowitz JE; Grieger JC; Govindasamy L; Agbandje-McKenna M; Xiao X; Samulski RJ
    Mol Ther; 2012 Feb; 20(2):443-55. PubMed ID: 22068425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs.
    Shin JH; Yue Y; Smith B; Duan D
    Hum Gene Ther; 2012 Mar; 23(3):287-94. PubMed ID: 22040468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus.
    Yue Y; Pan X; Hakim CH; Kodippili K; Zhang K; Shin JH; Yang HT; McDonald T; Duan D
    Hum Mol Genet; 2015 Oct; 24(20):5880-90. PubMed ID: 26264580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models.
    Hakim CH; Kumar SRP; Pérez-López DO; Wasala NB; Zhang D; Yue Y; Teixeira J; Pan X; Zhang K; Million ED; Nelson CE; Metzger S; Han J; Louderman JA; Schmidt F; Feng F; Grimm D; Smith BF; Yao G; Yang NN; Gersbach CA; Chen SJ; Herzog RW; Duan D
    Nat Commun; 2021 Nov; 12(1):6769. PubMed ID: 34819506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model.
    Kodippili K; Hakim CH; Pan X; Yang HT; Yue Y; Zhang Y; Shin JH; Yang NN; Duan D
    Hum Gene Ther; 2018 Mar; 29(3):299-311. PubMed ID: 28793798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.
    Siders WM; Shields J; Kaplan J; Lukason M; Woodworth L; Wadsworth S; Scaria A
    Hum Gene Ther; 2009 Jan; 20(1):11-20. PubMed ID: 18828728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.
    Le Hir M; Goyenvalle A; Peccate C; Précigout G; Davies KE; Voit T; Garcia L; Lorain S
    Mol Ther; 2013 Aug; 21(8):1551-8. PubMed ID: 23752313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duchenne muscular dystrophy gene therapy in the canine model.
    Duan D
    Hum Gene Ther Clin Dev; 2015 Mar; 26(1):57-69. PubMed ID: 25710459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles.
    Peccate C; Mollard A; Le Hir M; Julien L; McClorey G; Jarmin S; Le Heron A; Dickson G; Benkhelifa-Ziyyat S; Piétri-Rouxel F; Wood MJ; Voit T; Lorain S
    Hum Mol Genet; 2016 Aug; 25(16):3555-3563. PubMed ID: 27378686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.